[Comment] NAVIGATOR: physical activity for cardiovascular health?

In The Lancet, Thomas Yates and colleagues report new findings from the NAVIGATOR trial, a multicentre, international, randomised, placebo-controlled trial that examined the effect of nateglinide, valsartan, or both, on cardiovascular events in patients with impaired glucose tolerance and either existing cardiovascular disease or at least one additional risk factor. The results of this cohort analysis of the association between daily ambulatory activity, as assessed by pedometer, and a composite of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke, show a graded and independent inverse association of both baseline levels and change over a year of daily ambulatory activity and subsequent risk of a cardiovascular event—HR per 2000 steps per day 0·90 (95% CI 0·84–0·96) and 0·92 (0·86–0·99), respectively.

Source: LANCET - March 21, 2014 Category: Journals (General) Authors: Giuseppe Pugliese, Stefano Balducci Tags: Comment Source Type: research